BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29226391)

  • 1. Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.
    Silva JT; Pérez-González V; Lopez-Medrano F; Alonso-Moralejo R; Fernández-Ruiz M; San-Juan R; Brañas P; Folgueira MD; Aguado JM; de Pablo-Gafas A
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29226391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
    Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
    Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
    Rifkin LM; Minkus CL; Pursell K; Jumroendararasame C; Goldstein DA
    Ocul Immunol Inflamm; 2017 Feb; 25(1):93-96. PubMed ID: 26652481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.
    Chon WJ; Kadambi PV; Xu C; Becker YT; Witkowski P; Pursell K; Kane B; Josephson MA
    Case Rep Nephrol Dial; 2015; 5(1):96-105. PubMed ID: 26000278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
    Santhanakrishnan K; Yonan N; Iyer K; Callan P; Al-Aloul M; Venkateswaran R
    Transpl Infect Dis; 2022 Feb; 24(1):e13733. PubMed ID: 34534396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
    Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
    Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
    Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
    Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
    Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
    Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
    J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E; Lesnick T; Kremers W; Kennedy CC; Razonable RR
    Clin Transplant; 2016 Mar; 30(3):270-8. PubMed ID: 26701733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis.
    Solidoro P; Patrucco F; Libertucci D; Verri G; Sidoti F; Curtoni A; Boffini M; Simonato E; Rinaldi M; Cavallo R; Costa C
    Ther Adv Respir Dis; 2019; 13():1753466619878555. PubMed ID: 31566097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
    Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK
    Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches.
    Fu L; Santhanakrishnan K; Al-Aloul M; Jones NP; Steeples LR
    Ocul Immunol Inflamm; 2020 Oct; 28(7):1152-1158. PubMed ID: 31621449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.